Search results for "therapy [Encephalitis]"

showing 10 items of 2838 documents

Cyclophosphamide plus Epidoxorubicin and 5-Fluorouracil with Folinic Acid as a Novel Treatment in Metastatic Breast Cancer: Preliminary Results of a …

1991

Twenty consecutive patients with advanced breast cancer were treated with a combination of cyclophosphamide 600 mg/m2 i.v. on day 1, epidoxorubicin 75 mg/m2 on day 1, and 5-fluorouracil 375 mg/m2 i.v. with folinic acid 200 mg/m2 i.v. on days 1----3. The overall response rate was 60%, with 10% of patients showing a complete response with a mean duration of 11.1 + months, and 50% of patients a partial response of 7.4 + months. A stabilization of 5.2 + months was obtained in 20% of cases, while 20% of patients progressed. The most frequently observed toxicity was leukopenia, while expected mucosal toxicities were rather mild.

Adult0301 basic medicinemedicine.medical_specialtyCyclophosphamide030106 microbiologyLeucovorinPhases of clinical researchBreast NeoplasmsGastroenterologyMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisInfusions IntravenousCyclophosphamideEpirubicinPharmacologyLeukopeniabusiness.industryRemission InductionCancerMiddle Agedmedicine.diseaseMetastatic breast cancerSurgeryInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisDrug EvaluationFemaleFluorouracilmedicine.symptombusinessmedicine.drugJournal of Chemotherapy
researchProduct

Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma

2012

Oral metronomic chemotherapy is a therapeutic option which is particularly attractive due to its ease of administration and low toxic burden. Its mechanism of action probably involves antiangiogenetic effect rather than a classical antiproliferative effect like standard maximally tolerated dose-based regimens.A retrospective analysis of 61 patients with advanced breast carcinoma was carried out with the aim of reporting activity in terms of response rate, control of tumor-related symptoms, outcome, and toxicity. All patients had hormonal therapy-resistant metastatic disease and had previously received two lines of chemotherapy. The first cohort of 22 patients received oral cyclophosphamide …

AdultAged 80 and overAntineoplastic Combined Chemotherapy ProtocolNeoplasms Hormone-DependentSettore MED/06 - Oncologia MedicaPalliative CareAdministration OralBreast NeoplasmsMiddle AgedDisease-Free SurvivalDrug Administration ScheduleCohort StudiesMethotrexateAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleCohort StudieAntineoplastic Agents AlkylatingCyclophosphamideBreast NeoplasmAgedHumanNeoplasm StagingRetrospective Studies
researchProduct

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study.

2011

To retrospectively assess the efficacy of bendamustine alone and with rituximab (R-B), 109 patients with relapsed chronic lymphocytic leukaemia (CLL) were enrolled in 24 Italian centres. The median age was 66 years (range 39-85). Forty-three percent of patients had relapsed and 57% were resistant (median previous therapies = 3; range 1-8). Twenty-two patients received bendamustine alone and 87 patients received R-B (median B dosage: 100 mg/m(2) per day, range 90-130 mg/m(2) per day). The overall response rate was 69·6% (complete response 28·6%; partial response 41%), and was significantly higher in patients treated with R-B (P = 0·014) and in those responsive to the previous treatment (P=0·…

AdultAged 80 and overMaleAntineoplastic AgentsMiddle AgedLeukemia Lymphocytic Chronic B-CellAntibodies Monoclonal Murine-DerivedTreatment OutcomeDrug Resistance NeoplasmRecurrenceAntineoplastic Combined Chemotherapy ProtocolsNitrogen Mustard CompoundsBendamustine HydrochlorideDrug EvaluationHumanschronic lymphocytic leukemiaFemaleChronic lymphocytic leukemia; bendamustineBendamustinaEpidemiologic MethodsRituximabAged
researchProduct

Plasma granulysin levels and cellular interferon-gamma production correlate with curative host responses in tuberculosis, while plasma interferon-gam…

2007

Contains fulltext : 52707.pdf (Publisher’s version ) (Closed access) Granulysin is a recently identified cytolytic protein which is expressed by human cytotoxic T-lymphocytes and natural killer (NK)-cells, and has broad antimicrobial and tumoricidal activity. Circulating granulysin levels are associated with T- and NK-cell activity, and may thus reflect protection-associated cellular immune responses. In a case-control study in Indonesia, a highly tuberculosis (TB)-endemic country, we therefore determined plasma granulysin levels in adults with active pulmonary TB before, during, and after TB treatment, both in mild/moderate-TB and advanced-TB patients, and compared these to healthy neighbo…

AdultAntigens Differentiation T-LymphocyteMaleMicrobiology (medical)TuberculosisAdolescentInfectious diseases and international health [NCEBP 13]TuberculosiImmunologyEnzyme-Linked Immunosorbent AssayBiologySeverity of Illness IndexMicrobiologyInterferon-gammaImmune systemAntigenImmunitymedicineHumansCytotoxic T cellInterferon gammaPlasma granulysinCellular granulysinCellular IFN-gGranulysinDisease severityTuberculosis PulmonaryAgedImmunity CellularInterferon-gamma productionPoverty-related infectious diseases [N4i 3]Immunotherapy gene therapy and transplantation [UMCN 1.4]Middle Agedmedicine.diseasePathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCase-Control StudiesPlasma IFN-gImmunologyFemaleMicrobial pathogenesis and host defense [UMCN 4.1]medicine.drugImmunity infection and tissue repair [NCMLS 1]
researchProduct

Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor s…

1997

Fifty-five consecutive patients with metastatic breast cancer (MBC) (n = 57) were treated with a combination of levofolinic acid (I-FA) 100 mg/m2 plus 5-fluorouracil (5-FU) 340 mg/m2 i.v. on day 1-3, cyclophosphamide (CTX) 600 mg/m2 i.v. on day 1 and mitoxantrone (DHAD) 12 mg/m2 i.v. on day 1. DHAD dose was progressively escalated by 2 mg/m2/cycle up to 18 mg/m2 in the absence of dose-limiting toxicities. Granulocyte colony stimulating factor (G-CSF) was given s.c. in order to prevent neutropenia. DHAD dosage could be increased to 18 mg/m2 in 66 out of 317 cycles of chemotherapy (21%). In most patients the dose-limiting toxicity was represented by myelosuppression. A statistically significa…

AdultAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentAntidotesLeucovorinAntineoplastic AgentsBreast NeoplasmsPharmacologyNeutropeniaGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicinePharmacology (medical)Antineoplastic Agents AlkylatingCyclophosphamideAgedPharmacologyMitoxantroneChemotherapybusiness.industryMiddle Agedmedicine.diseaseMetastatic breast cancerGranulocyte colony-stimulating factorItalyOncologyToxicityAbsolute neutrophil countFemaleFluorouracilMitoxantronebusinessmedicine.drugAnti-Cancer Drugs
researchProduct

Inter-individual variation in response to resistance training in cardiometabolic health indicators.

2020

Resistance training (RT) may improve metabolic health; however, the extent of its effectiveness is constantly evaluated to assess improvements in the group means, thus obscuring the heterogeneous individual effects. This study investigated inter-individual variation in response to RT as reflected in metabolic health indicators and how age, sex, nutrition, and pre-training phenotypes are associated with such variabilities. Methods Previously collected data of men and women (39-73 years, 135 trained, 73 non-trained controls) were pooled for analysis. Measurements were taken twice before training to estimate individual day-to-day variations and measurement errors (n = 208). The individual resp…

AdultBlood GlucoseMalePhysiologyBlood lipidsNutritional StatusPhysical Therapy Sports Therapy and RehabilitationBlood Pressure030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHealth caremedicineHumansInsulinOrthopedics and Sports MedicineTriglyceridesAged2. Zero hungerMetabolic Syndromemedicine.diagnostic_testCholesterolbusiness.industryIncidence (epidemiology)Resistance Training030229 sport sciencesMiddle Agedmedicine.diseaseHealth indicator3. Good healthBlood pressureCholesterolchemistryBody CompositionFemaleMetabolic syndromebusinessLipid profileScandinavian journal of medicinescience in sportsREFERENCES
researchProduct

Physical Activity, Fitness, Glucose Homeostasis, and Brain Morphology in Twins

2014

The main aim of the present study (FITFATTWIN) was to investigate how physical activity level is associated with body composition, glucose homeostasis, and brain morphology in young adult male monozygotic twin pairs discordant for physical activity.From a population-based twin cohort, we systematically selected 10 young adult male monozygotic twin pairs (age range, 32-36 yr) discordant for leisure time physical activity during the past 3 yr. On the basis of interviews, we calculated a mean sum index for leisure time and commuting activity during the past 3 yr (3-yr LTMET index expressed as MET-hours per day). We conducted extensive measurements on body composition (including fat percentage …

AdultBlood GlucoseMalemedicine.medical_specialtyPhysical fitnessPopulationMonozygotic twinPhysical Therapy Sports Therapy and RehabilitationMotor ActivityBiology03 medical and health sciencesLeisure Activities0302 clinical medicineInternal medicinemedicineHomeostasisHumansGlucose homeostasisOrthopedics and Sports Medicine030212 general & internal medicinegray matter volumeeducationta315education.field_of_studybody compositionexercisebusiness.industryBrain morphometryBrainta3141Twins MonozygoticMagnetic Resonance ImagingTwin studyPhysical activity levelfitnessEndocrinologyPhysical Fitnessglocosebusiness030217 neurology & neurosurgeryHomeostasisMedicine and Science in Sports and Exercise
researchProduct

Associations of Maximal Strength and Muscular Endurance with Cardiovascular Risk Factors

2013

The aim was to study the associations of maximal strength and muscular endurance with single and clustered cardiovascular risk factors. Muscular endurance, maximal strength, cardiorespiratory fitness and waist circumference were measured in 686 young men (25±5 years). Cardiovascular risk factors (plasma glucose, serum high- and low-density lipoprotein cholesterol, triglycerides, blood pressure) were determined. The risk factors were transformed to z-scores and the mean of values formed clustered cardiovascular risk factor. Muscular endurance was inversely associated with triglycerides, s-LDL-cholesterol, glucose and blood pressure (β=-0.09 to - 0.23, p0.05), and positively with s-HDL choles…

AdultBlood GlucoseMalemedicine.medical_specialtyWaistBlood PressurePhysical Therapy Sports Therapy and Rehabilitation030204 cardiovascular system & hematologyCardiovascular Physiological PhenomenaYoung Adult03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsInternal medicinemedicineHumansAerobic exerciseOrthopedics and Sports MedicineMuscle StrengthRisk factorYoung adultTriglyceridesbusiness.industryCholesterol HDLCardiorespiratory fitnessCholesterol LDL030229 sport sciencesmedicine.diseaseBlood pressureEndocrinologyCardiovascular DiseasesPhysical FitnessPhysical EnduranceWaist CircumferenceMetabolic syndromebusinessInternational Journal of Sports Medicine
researchProduct

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with plati…

2004

OBJECTIVES: There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1…

AdultBridged-Ring Compoundsmedicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPharmacologyNeutropeniaGastroenterologyDrug Administration Schedulechemistry.chemical_compoundRefractoryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansExatecanEnzyme InhibitorsAgedOvarian NeoplasmsChemotherapyTaxanebusiness.industryObstetrics and GynecologyExatecan mesylateMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicDrug Resistance MultipleRegimenOncologychemistryDrug Resistance NeoplasmCamptothecinFemaleTaxoidsTopoisomerase I InhibitorsbusinessOvarian cancer
researchProduct

Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma

1993

Twenty-two women affected by metastatic breast carcinoma have been treated with a combination of levo folinic acid 100 mg/m 2 plus 5-fluorouracil 450 mg/m 2 i.v. on day 1-2, and epidoxorubicin 75-90 mg/m 2 on day 2. This treatment cycle was repeated every 21-28 days. No patients had previously received chemotherapy for metastatic disease. Fourteen patients (64%) showed a major objective response with 3 complete (14%) and 11 partial responses (50%). Three patients showed a stabilization of disease and 5 (23%) progressed. All patients received ondansetron as antiemetic treatment which led to complete protection from vomiting in 68% of cases. Grade 1-2 diarrhea was recorded in 27% of the patie…

AdultCancer Research5-flurouracilDose-Response Relationship DrugLevo folinic acidCarcinomaLeucovorinBreast NeoplasmsMiddle AgedBreast cancerCarcinoma Intraductal NoninfiltratingOncologyEpidoxorubicinAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleFluorouracilAgedEpirubicin
researchProduct